Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + gemcitabine + oxaliplatin
- Development stage
- Phase 2
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Capecitabine + gemcitabine + oxaliplatin is a triple-drug chemotherapy regimen used primarily in the treatment of advanced or metastatic pancreatic cancer and biliary tract cancers. This combination brings together three cytotoxic agents with distinct mechanisms of action: - Capecitabine is an oral prodrug that is converted to 5-fluorouracil (5-FU) preferentially in tumor tissue, where it inhibits thymidylate synthase and disrupts DNA synthesis. - Gemcitabine is a nucleoside analog that incorporates into DNA during replication, causing chain termination and apoptosis. - Oxaliplatin is a platinum-based agent that forms cross-links within DNA strands, inhibiting replication and transcription. The regimen has been studied under names such as GEMOXEL. Clinical trials have shown this combination to be feasible with manageable toxicity profiles and promising efficacy as first-line therapy for advanced pancreatic adenocarcinoma[1][2][3][5]. It has also been explored for use in advanced biliary tract cancers[5].
- Brand names
- GEMOXEL
- Other names
- GEMOXELGEMOX-CAPgemcitabine/oxaliplatin/capecitabine combination
02
Targets
DNADNA polymerase familyRNR (Ribonucleotide reductase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on capecitabine + gemcitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + gemcitabine + oxaliplatin.